Ipriflavone|CAS 35212-22-7|DC Chemicals

Cas No.:	35212-22-7
Chemical Name:	ipriflavone
Synonyms:	ipriflavone;7-Isopropoxyisoflavone;3-phenyl-7-propan-2-yloxychromen-4-one;7-Isopropoxy-3-phenyl-4H-1-benzopyran-4-one;IPRIFLAVONE(P);4-isopropoxyisoflavone;7-isopropoxy-isoflavone;7-isopropyloxy-isoflavone;FL-113;Ipriflavone (Osteofix);Osten;Osteofix;Osteoquine;Yambolap;7-Isoproxyisoflavone;7-(1-Methylethoxy)-3-phenyl-4H-1-benzopyron-4-one;FT-0621442;D70301;NCGC00024094-04;Iprivone;Opera_ID_1176;DTXSID5040679;D01338;UNII-80BJ7WN25Z;NCGC00018139-02;HMS3715D04;SR-01000000042;IPRIFLAVONE [JAN];HMS3371E17;AMY25650;HMS3656K19;Tox21_111532_1;CHEBI:31719;Oprea1_106310;Quinogin;7-Isopropoxy-3-phenyl-4H-1-benzopyran-4-one, 97%;IPRIFLAVONE [VANDF];CHEMBL165790;Ipriflavone, analytical standard;Oprea1_275552;TC 80;CS-6395;NC00213;IPRIFLAVONE [INN];SFBODOKJTYAUCM-UHFFFAOYSA-;NSC 755888;MFCD00221719;Tox21_113172;BRN 4754346;FL113;Ipriflavona;MLS000069470;Osten (TN);AB00384280-21;NCGC00018139-07;IPRIFLAVONE [MI];Ipriflavonum [INN-Latin];HMS3393J15;SMR000059060;NCGC00018139-03;CAS-35212-22-7;MLS001424060;A822650;7-isopropoxy-3-phenyl-chromone;Ostivone;s2422;Tox21_113172_1;BDBM43662;7-(1-Methylethoxy)-3-phenyl-4H-1-benzopyran-4-one;DB13618;Iprosten;NCGC00018139-05;Ipriflavone, INN;TC-80;NCGC00018139-01;Ipriflavone (JP17/INN);HMS2051J15;CCRIS 1920;cid_3747;Ipriflavonum;Osteochin;NCGC00018139-08;Ipriflavone [INN:JAN];(Ipriflavone);3-phenyl-7-propan-2-yloxy-1-benzopyran-4-one;SW197593-2;HY-N0094;CCG-100963;AC-8130;TN-39;SR-01000000042-2;3-phenyl-7-(propan-2-yloxy)-4H-chromen-4-one;I0669;FL 113;35212-22-7;MLS001146879;4H-1-Benzopyran-4-one, 7-(1-methylethoxy)-3-phenyl-;Q1097778;NCGC00018139-04;NSC-755888;Cambridge id 6663564;80BJ7WN25Z;HMS2234M05;InChI=1/C18H16O3/c1-12(2)21-14-8-9-15-17(10-14)20-11-16(18(15)19)13-6-4-3-5-7-13/h3-12H,1-2H3;Ipriflavona [INN-Spanish];Ipriflavon;AKOS003627375;Ipriflavone (JAN/INN);7-isopropoxy-3-phenyl-4H-chromen-4-one;F0196-0909;3-phenyl-7-propan-2-yloxy-chromen-4-one;NS00010326;Tox21_111532;AS-12306;MLS006011644;DTXCID3020679;SCHEMBL111472;MLS000759494;IPRIFLAVONE [WHO-DD];IPRIFLAVONE [MART.];STL512460;DB-048754;BRD-K93618743-001-21-0;Ipriflavone (JP18/INN);BRD-K93618743-001-20-2
SMILES:	O=C1C(C2=CC=CC=C2)=COC3=CC(OC(C)C)=CC=C13
Formula:	C₁₈H₁₆O₃
M.Wt:	280.31784
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Cat. No.	Product name	Field of application
DC31074	Isopropyl myristate	Isopropyl myristate is the ester of isopropyl alcohol and myristic acid.
DC75868	AZ14133346	AZ14133346 (compound 36) is a potent and selective inhibitor of EGFR Exon20 insertions, with the IC50 of 85 nM. AZ14133346 plays an important role in cancer research.
DC75865	TI17	TI17 represents a novel class of targeted anticancer agents that specifically disrupt DNA damage repair mechanisms in malignant cells.
DC75816	Nisoxetine	Nisoxetine acts as a highly selective and potent noradrenaline transporter (NET) antagonist, exhibiting a binding affinity (Kd) of 0.76 nM. In addition to its antidepressant properties, nisoxetine functions as a local anesthetic by inhibiting voltage-gated sodium channels. This dual pharmacological activity makes it a compound of interest for both neurological and pain management research.
DC75641	GENZ-644282 TFA salt	Genz-644282, also known as SAR402674, is a non-camptothecin inhibitor of topoisomerase I with potential antineoplastic activity. Topoisomerase I inhibitor Genz-644282 binds to and inhibits the enzyme topoisomerase I, which may result in the inhibition of repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations.
DC75325	PSMA-617 TFA	PSMA-617, also know as vipivotide tetraxetan, is a ligand used to make 177Lu-PSMA-617, which is a radioactive molecule to fight cancer. PSMA617 possesses a small peptide, which was designed to target prostate-specific membrane antigen (PSMA). PSMA617 demonstrates high radiolytic stability for at least 72 h. PSMA617 has high inhibition potency (equilibrium dissociation constant Ki=2.34±2.94 nM on LNCaP; Ki=0.37±0.21 nM enzymatically determined). 177 Lu-PSMA-617 offers a potential additional life-prolonging treatment option for men with mCRPC.
DC75202	Fosaprepitant free acid	Fosaprepitant, also known as MK0517, is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant. Fosaprepitant was developed by Merck & Co. and was approved. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. Fosaprepitant is a weak inhibitor of CYP3A4, and aprepitant, the active moiety, is a substrate, inhibitor, and inducer of CYP3A4
DC74748	O4I4	O4I4 (compound 23) is a OCT4-inducing compound with metabolical stability.
DC74684	ZH8667	ZH8667 is a trace amine-associated receptor 1 (TAAR1)–Gs agonist.
DC74646	EB-PSMA-617	EB-PSMA-617 is an Evans blue-modified prostate-specific membrane antigen (PSMA) 617 ligand for making 177Lu-EB-PSMA, which is potential useful for Metastatic Castration-Resistant Prostate Cancer.